For pre-exposure prophylaxis (PrEP) and microbicides to effectively prevent HIV, optimal treatment adherence is required. Adherence to these strategies, however, has not been sufficiently studied. This investigation systematically reviews oral PrEP and microbicide trials across 4 domains of adherence: (1) definition and measures used, (2) risks for nonadherence, (3) promotion strategies, and (4) effects on outcomes. Nineteen (n = 19) trials, with 47,157 participants, published between 1987 and 2012 were identified. Reported mean adherence to microbicides was 79% and to oral PrEP 87%. Common risks for microbicide nonadherence were decreased motivation over time, sex with primary (noncommercial/casual) partners, and insufficient supply. Oral PrEP nonadherence risks were older age and medication side effects. Psychoeducation and outreach to participants and communities were frequently used promotion strategies. Most trials failed to systematically identify barriers and monitor and promote adherence, although adherence moderated outcomes. Recommendations for attending to adherence in future trials are provided.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068619 | PMC |
| http://dx.doi.org/10.1097/QAI.0b013e31826f9962 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acceptability and feasibility of a urine-based tenofovir adherence assay for monitoring and providing feedback on PrEP adherence in Kenya.
AIDS Care
December 2024
School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Objective measures of oral PrEP adherence - especially point-of-care (POC) measures that enable real-time assessment, intervention, and feedback - have the potential to improve adherence. Our team previously developed and validated a novel urine-based POC metric of PrEP adherence. In this study, we sought to determine whether this assay is acceptable and feasible among women taking PrEP and PrEP providers in Kenya.
View Article and Find Full Text PDFBarriers to PrEP use and adherence among adolescent girls and young women in Eastern, Southern, and Western Africa: a scoping review.
BMC Womens Health
December 2024
Department of Public Health Institute of Tropical Medicine, Antwerp, Belgium.
Background: Adolescent girls and young women (AGYW) are disproportionately affected by HIV. Globally, in 2022, an estimated 4000 AGYW 15-24 were newly infected with HIV weekly, and nearly 78% of these infections occurred in sub-Saharan Africa. Oral Pre-Exposure Prophylaxis (PrEP) is a key HIV prevention option within an overall HIV combination prevention approach with an efficacy of over 90% when taken correctly.
View Article and Find Full Text PDFOral pre-exposure prophylaxis implementation in South Africa: a case study of USAID-supported programs.
Front Reprod Health
December 2024
Bilateral Health Office, United States Agency for International Development, Pretoria, South Africa.
Since the introduction of oral pre-exposure prophylaxis (PrEP) in 2016, countries have successfully scaled-up PrEP to populations at risk of HIV acquisition, including key populations, serodiscordant couples and pregnant women. Between 2016 and 2023, there were over 5.6 million oral PrEP initiations globally.
View Article and Find Full Text PDF"Youth are experts in what they need": experiences and best practice in co-designing and implementing Fast-PrEP, a novel PrEP service for adolescents and youth in Cape Town, South Africa.
Front Public Health
December 2024
Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa.
Introduction: Defining the prevention needs, motivations, and gender dynamics influencing adolescent and young people's (AYP's) healthcare access is a key component to successful PrEP (pre-exposure prophylaxis for HIV prevention) implementation. WHO encourages a strong people-cantered approach to healthcare delivery, and this is particularly emphasized for HIV services. Enhanced youth engagement is needed to ensure that interventions are tailored to the specific needs and preferences of youth populations.
View Article and Find Full Text PDFLongitudinal changes in tenofovir and tenofovir-diphosphate concentrations among pregnant women using oral PrEP for HIV prevention: Findings from Durban, South Africa.
J Acquir Immune Defic Syndr
December 2024
Division of Infectious Diseases, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA.
Background: Pregnant women are vulnerable to HIV acquisition. Oral HIV pre-exposure prophylaxis (PrEP) is safe and effective for use during pregnancy. We describe PrEP adherence among pregnant women using multiple measures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!